Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Am J Emerg Med ; 38(7): 1543.e1-1543.e2, 2020 07.
Article in English | MEDLINE | ID: mdl-32305154

ABSTRACT

Anaplasma phagocytophilum (AP) is the causative agent of human granulocytic anaplasmosis (HGA), a tick-borne illness with highest incidence in north-eastern regions of the United States. This condition presents with vague constitutional symptoms and has been associated with laboratory derangements such as leukopenia, thrombocytopenia and transaminitis1. Rhabdomyolysis, however, is not one of these associations. We report a case of confirmed HGA associated with severe rhabdomyolysis, where no other cause was identified. The etiology of rhabdomyolysis secondary to AP infection is still unknown. A presumptive diagnosis of HGA can be made in the presence of fever, non-specific symptoms such as myalgias, laboratory derangements such as leukopenia and thrombocytopenia in an individual residing in an endemic area3. Serological confirmation should not delay treatment, given the rapid progression of this dangerous infection. Rhabdomyolysis should also be considered as part of supporting data in the diagnostic consideration for HGA.


Subject(s)
Anaplasma phagocytophilum/pathogenicity , Anaplasmosis/microbiology , Rhabdomyolysis/microbiology , Adult , Female , Humans , Leukopenia/microbiology , Thrombocytopenia/microbiology
2.
Cerebrovasc Dis ; 43(3-4): 99-109, 2017.
Article in English | MEDLINE | ID: mdl-28049200

ABSTRACT

BACKGROUND: Stroke-induced immunodeficiency increases the risk of infectious complications, which adversely affects neurological outcome. Among those, pneumonia affects as many as one third of stroke patients and is the main contributor to mortality in the post-acute phase of stroke. Experimental findings on post-stroke susceptibility to spontaneous pneumonia in mice are contradictory. Here, we established a mouse model inducing standardized bacterial pneumonia and characterized the impaired pulmonary cellular and humoral immune responses after experimental stroke. METHODS: Bacterial pneumonia was induced by intra-tracheal inoculation with Streptococcus pneumoniae at different time points after transient middle cerebral artery occlusion (MCAO). Bacterial counts in lungs and blood, histological changes, and cytokine production in the lungs were assessed. Furthermore, we investigated the effect of pneumonia on stroke outcome. RESULTS: Intra-tracheal inoculation resulted in reproducible pneumonia and bacteraemia, and demonstrated post-stroke susceptibility to streptococcal pneumonia developing with a delay of at least 24 h after MCAO. Higher bacterial counts in mice infected 3 days after stroke induction correlated with reduced neutrophil and macrophage infiltration in the lungs and lower levels of pro-inflammatory cytokines in the broncho-alveolar lavage compared to sham-operated animals. Pneumonia increased mortality without affecting brain-infiltrating leukocytes. CONCLUSIONS: In this standardized mouse model of post-stroke pneumonia, we describe attenuated leukocyte infiltration and cytokine production in response to bacterial infection in the lungs that has a profound effect on outcome.


Subject(s)
Immunocompromised Host , Infarction, Middle Cerebral Artery/immunology , Lung/microbiology , Opportunistic Infections/microbiology , Pneumonia, Pneumococcal/microbiology , Streptococcus pneumoniae/pathogenicity , Animals , Cytokines/metabolism , Disease Models, Animal , Host-Pathogen Interactions , Inhalation Exposure , Leukopenia/blood , Leukopenia/immunology , Leukopenia/microbiology , Lung/immunology , Lung/metabolism , Macrophages/immunology , Macrophages/metabolism , Macrophages/microbiology , Male , Mice, Inbred C57BL , Neutrophil Infiltration , Neutrophils/immunology , Neutrophils/metabolism , Neutrophils/microbiology , Opportunistic Infections/blood , Opportunistic Infections/immunology , Pneumonia, Pneumococcal/blood , Pneumonia, Pneumococcal/immunology , Streptococcus pneumoniae/immunology , Time Factors
3.
Blood ; 129(6): 729-739, 2017 02 09.
Article in English | MEDLINE | ID: mdl-27879260

ABSTRACT

Bone marrow suppression is an adverse effect associated with many antibiotics, especially when administered for prolonged treatment courses. Recent advances in our understanding of steady-state hematopoiesis have allowed us to explore the effects of antibiotics on hematopoietic progenitors in detail using a murine model. Antibiotic-treated mice exhibited anemia, thrombocytosis, and leukopenia, with pronounced pan-lymphopenia as demonstrated by flow cytometric analysis of peripheral blood. Bone marrow progenitor analysis revealed depletion of hematopoietic stem cells and multipotent progenitors across all subtypes. Granulocytes and B cells were also diminished in the bone marrow, whereas the number of CD8+ T cells increased. Reductions in progenitor activity were not observed when cells were directly incubated with antibiotics, suggesting that these effects are indirect. Hematopoietic changes were associated with a significant contraction of the fecal microbiome and were partially rescued by fecal microbiota transfer. Further, mice raised in germ-free conditions had hematopoietic abnormalities similar to those seen in antibiotic-treated mice, and antibiotic therapy of germ-free mice caused no additional abnormalities. The effects of antibiotics were phenocopied in Stat1-deficient mice, with no additional suppression by antibiotics in these mice. We conclude that microbiome depletion as a result of broad-spectrum antibiotic treatment disrupts basal Stat1 signaling and alters T-cell homeostasis, leading to impaired progenitor maintenance and granulocyte maturation. Methods to preserve the microbiome may reduce the incidence of antibiotic-associated bone marrow suppression.


Subject(s)
Anemia/chemically induced , Anti-Bacterial Agents/adverse effects , Gastrointestinal Microbiome/drug effects , Hematopoiesis/drug effects , Leukopenia/chemically induced , STAT1 Transcription Factor/genetics , Thrombocytosis/chemically induced , Anemia/microbiology , Anemia/pathology , Anemia/therapy , Animals , B-Lymphocytes/drug effects , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/pathology , Fecal Microbiota Transplantation , Gastrointestinal Microbiome/physiology , Gene Expression , Germ-Free Life/drug effects , Germ-Free Life/genetics , Granulocytes/drug effects , Granulocytes/metabolism , Granulocytes/pathology , Hematopoiesis/genetics , Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/pathology , Leukopenia/microbiology , Leukopenia/pathology , Leukopenia/therapy , Macrophages/drug effects , Macrophages/metabolism , Macrophages/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , STAT1 Transcription Factor/deficiency , Signal Transduction , Thrombocytosis/microbiology , Thrombocytosis/pathology , Thrombocytosis/therapy
4.
Infez Med ; 23(2): 178-81, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26110300

ABSTRACT

Although liver involvement is frequently seen in brucellosis, acute hepatitis is a rare clinical entity. In its progress, haematological findings are non-specific and vary in respect to severity. In this paper, we present a case of brucellosis with acute hepatitis and bicytopenia without anaemia. A 19-year-old man presented with a 2-week history of fever, sweating, low back and leg pain, lassitude, loss appetite, nausea and vomiting. He gave a history of raw milk ingestion and animal contact. Physical examination showed signs of icteric skin and sclera, tenderness in the right hypochondriac region and hepatosplenomegaly. On admission to hospital, laboratory tests showed WBC 3500/mmc (polymorphs 63% and lymphocytes 33%), haemoglobin 13.8 g/dL, platelet 89000/mmc, erythrocyte sedimentation rate 19 mm/h, and C-reactive protein 21.7 mg/dL (N<0.8 mg/dL). Biochemical tests were as follows: AST 771 U/L, ALT 471 U/L, ALP 355 U/L, GGT 432 U/L, total bilirubin 2.61 mg/dL, direct bilirubin 1.45 mg/dL and albumin 3.7 g/dL. Viral hepatitis markers were found to be negative (HBsAg, anti-HBc total, anti-HBc IgM, anti-HAV IgM, and anti-HCV). Blood culture grew Brucella melitensis. Leukopenia and thrombocytopenia returned to normal levels at the 7th and 14th day of his admission, respectively. Liver function tests improved at the 28th day. Treatment of the brucellosis was performed with antibiotics (tetracycline 500 mg orally four times daily for 6 weeks and streptomycin 1 g IM once daily for 21 days). Finally, a case of brucellosis with acute hepatitis and bicytopenia was treated with a successful outcome. In conclusion, we suggest that due consideration be taken of bicytopenia/pancytopenia and acute hepatitis in brucellosis cases in Turkey, an endemic region.


Subject(s)
Brucella melitensis/isolation & purification , Brucellosis/complications , Hepatitis/microbiology , Leukopenia/microbiology , Thrombocytopenia/microbiology , Acute Disease , Adult , Anti-Bacterial Agents/therapeutic use , Brucellosis/diagnosis , Drug Therapy, Combination , Hepatitis/diagnosis , Hepatitis/drug therapy , Humans , Male , Streptomycin/therapeutic use , Tetracycline/therapeutic use , Treatment Outcome , Turkey
6.
J Thromb Haemost ; 13(6): 1090-102, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25851247

ABSTRACT

BACKGROUND AND OBJECTIVES: Carboxypeptidase B2 (CPB2) is a basic carboxypeptidase with fibrin and complement C3a and C5a as physiological substrates. We hypothesized that in polymicrobial sepsis, CPB2-deficient mice would have sustained C5a activity, leading to disease exacerbation. METHODS: Polymicrobial sepsis was induced by cecal ligation and puncture (CLP). RESULTS: Contrary to our hypothesis, Cpb2(-/-) mice had significantly improved survival, with reduced lung edema, less liver and kidney damage, and less disseminated intravascular coagulation. Hepatic pro-CPB2 was induced by CLP, leading to increased pro-CPB2 levels. Thrombomodulin present on mesothelium supported thrombin activation of pro-CPB2. Both wild-type and Cpb2(-/-) animals treated with a C5a receptor antagonist had improved survival, demonstrating that C5a was detrimental in this model. Treatment with a fibrinolysis inhibitor, tranexamic acid, caused a decrease in survival in both genotypes; however, the Cpb2(-/-) animals retained their survival advantage. Administration of a C3a receptor antagonist exacerbated the disease in both wild-type and Cpb2(-/-) mice and eliminated the survival advantage of Cpb2(-/-) mice. C5a receptor is expressed in both peritoneal macrophages and neutrophils; in contrast, C3a receptor expression is restricted to peritoneal macrophages, and C3a induced signaling in macrophages but not neutrophils. CONCLUSIONS: While C5a exacerbates the peritonitis, resulting in a deleterious generalized inflammatory state, C3a activation of peritoneal macrophages may limit the initial infection following CLP, thereby playing a diametrically opposing protective role in this polymicrobial sepsis model.


Subject(s)
Carboxypeptidase B2/deficiency , Complement C3a/metabolism , Complement C5a/metabolism , Peritonitis/enzymology , Sepsis/enzymology , Animals , Antifibrinolytic Agents/pharmacology , Blood Coagulation Disorders/enzymology , Blood Coagulation Disorders/genetics , Blood Coagulation Disorders/immunology , Blood Coagulation Disorders/microbiology , Carboxypeptidase B2/genetics , Cecum/microbiology , Cecum/surgery , Cells, Cultured , Complement C3a/antagonists & inhibitors , Complement C3a/immunology , Complement C5a/antagonists & inhibitors , Complement C5a/immunology , Disease Models, Animal , Enzyme Activation , Fibrin/metabolism , Inflammation Mediators/blood , Leukopenia/enzymology , Leukopenia/genetics , Leukopenia/immunology , Leukopenia/microbiology , Ligation , Liver/enzymology , Liver/immunology , Liver/microbiology , Macrophage Activation , Macrophages, Peritoneal/enzymology , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/microbiology , Male , Mice, Inbred C57BL , Mice, Knockout , Peritonitis/genetics , Peritonitis/immunology , Peritonitis/microbiology , Protective Factors , Punctures , Risk Factors , Sepsis/genetics , Sepsis/immunology , Sepsis/microbiology , Thrombin/metabolism , Thrombomodulin/metabolism , Time Factors
7.
J Trauma Acute Care Surg ; 78(3): 468-73; discussion 473-4, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25710415

ABSTRACT

BACKGROUND: The diagnosis of ventilator-associated pneumonia (VAP) in our institution has followed an established diagnostic threshold (DT) of equal to or greater than 10 colony-forming units (CFU) per milliliter on bronchoalveolar lavage (BAL) based on our previous study (PS). Because mortality from VAP is related to treatment delay, some have advocated a lower DT. The purpose of the current study (CS) was to evaluate the impact of adherence to this DT for VAP on false-negative (FN) rates and mortality in trauma patients. METHODS: Consecutive patients over 9 years with VAP (defined as ≥10 CFU/mL in the BAL effluent) subsequent to the PS were identified. Data regarding each BAL performed and the colony counts of each organism identified were recorded. An FN BAL result was defined as any patient who had less than 10 CFU/mL and developed VAP with the same organism up to 7 days after the previous culture. The CS was then compared with the PS. RESULTS: Over 9 years, 1,679 patients underwent 3,202 BALs. Of these, 79% were male, 88% experienced blunt injury, mean age and Injury Severity Score (ISS) were 44 years and 31, respectively. Overall, there were 73 FN BAL results (2.3%) in the CS compared with 3% in the PS (p = 0.092). In those patients with 10 organisms, the FN rate was reduced (7.5% vs. 11%, p = 0.045), and mortality was unchanged (5.4% vs. 8.3%, p = 0.361) in the CS compared with the PS. The use of the threshold equal to or greater than 10 resulted in a cumulative reduction in antibiotic charges of $1.57 million. CONCLUSION: Continued adherence to the diagnostic threshold of equal to or greater than 10 for quantitative BAL in trauma patients has maintained a low incidence of FN BALs and reduced patient charges without impacting mortality. The purported benefit of a lower threshold is not supported. In addition, the potential sequelae of increased resistant organisms, antibiotic-related complications, and costs associated with prolonged unnecessary antibiotic exposure are minimized. LEVEL OF EVIDENCE: Prognostic study, level III.


Subject(s)
Bronchoalveolar Lavage , Cross Infection/diagnosis , Pneumonia, Bacterial/diagnosis , Pneumonia, Ventilator-Associated/diagnosis , Adult , Algorithms , Anti-Bacterial Agents/therapeutic use , Bronchoscopy , Colony Count, Microbial , Cross Infection/drug therapy , Cross Infection/microbiology , Diagnosis, Differential , False Negative Reactions , Female , Humans , Injury Severity Score , Intensive Care Units , Leukocytosis/microbiology , Leukopenia/microbiology , Male , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/microbiology , Pneumonia, Ventilator-Associated/drug therapy , Pneumonia, Ventilator-Associated/microbiology , Prospective Studies , Radiography, Thoracic , Trauma Centers
8.
BMC Infect Dis ; 13: 359, 2013 Aug 01.
Article in English | MEDLINE | ID: mdl-23915338

ABSTRACT

BACKGROUND: Necrotizing pneumonia attributed to Panton-Valentine leukocidin-positive Staphylococcus aureus has mainly been reported in otherwise healthy children and young adults, with a high mortality rate. Erythroderma, airway bleeding, and leukopenia have been shown to be predictive of mortality. The objectives of this study were to define the characteristics of patients with severe leukopenia at 48-h hospitalization and to update our data regarding mortality predicting factors in a larger population than we had previously described. METHODS: It was designed as a case-case study nested in a cohort study. A total of 148 cases of community-acquired, necrotizing pneumonia were included. The following data were collected: basic demographic information, medical history, signs and symptoms, radiological findings and laboratory results during the first 48 h of hospitalization. The study population was divided into 2 groups: (1) with severe leukopenia (leukocyte count ≤3,000 leukocytes/mL, n=62) and (2) without severe leukopenia (>3,000 leukocytes/mL, n=86). RESULTS: Median age was 22 years, and the male-to-female gender ratio was 1.5. The overall in-hospital mortality rate was 41.2%. Death occurred in 75.8% of severe leukopenia cases with median survival time of 4 days, and in 16.3% of cases with leukocyte count >3,000/mL (P<0.001). Multivariate analysis indicated that the factors associated with severe leukopenia were influenza-like illness (adjusted odds ratio (aOR) 4.45, 95% CI (95% confidence interval) 1.67-11.88, P=0.003), airway bleeding (aOR 4.53, 95% CI 1.85-11.13, P=0.001) and age over 30 years (aOR 2.69, 95% CI 1.08-6.68, P=0.033). A personal history of furuncles appeared to be protective (OR 0.11, 95% CI 0.01-0.96, P=0.046). CONCLUSION: S. aureus-necrotizing pneumonia is still an extremely severe disease in patients with severe leukopenia. Some factors could distinguish these patients, allowing better initial identification to initiate adapted, rapid administration of appropriate therapy.


Subject(s)
Community-Acquired Infections/microbiology , Leukopenia/microbiology , Pneumonia, Staphylococcal/microbiology , Staphylococcus aureus/isolation & purification , Adolescent , Adult , Bacterial Toxins/metabolism , Child , Child, Preschool , Cohort Studies , Community-Acquired Infections/epidemiology , Community-Acquired Infections/pathology , Exotoxins/metabolism , Female , Hospital Mortality , Humans , Kaplan-Meier Estimate , Leukocidins/metabolism , Leukocyte Count , Leukopenia/epidemiology , Leukopenia/pathology , Male , Multivariate Analysis , Necrosis , Pneumonia, Staphylococcal/epidemiology , Pneumonia, Staphylococcal/pathology , Risk Factors
9.
Mayo Clin Proc ; 87(3): 233-9, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22386178

ABSTRACT

OBJECTIVE: To describe clinical findings and the use of a tick-associated pathogen panel in a series of patients with human granulocytic anaplasmosis (HGA) at a suburban Boston hospital. PATIENTS AND METHODS: Medical records were reviewed for inpatients and outpatients at Newton-Wellesley Hospital with a positive polymerase chain reaction (PCR) result for Anaplasma phagocytophilum during the study period March 1 through November 30, 2009. A PCR panel was used to test for tick-borne pathogens. Postal ZIP code data from the patients' areas of residence were used to estimate the area of disease transmission. RESULTS: Thirty-three cases were confirmed during the 2009 transmission season, and 14 of these patients (42%) required hospitalization. Thrombocytopenia and/or leukopenia were observed at the time of presentation in 25 of 30 patients (86%) in whom both white blood cell and platelet counts were determined, and 28 of 33 patients (85%) reported fever. Rash occurred in only 2 of the 33 patients (6%), and 25 (76%) reported one or more respiratory or gastrointestinal symptom. Cases were geographically distributed diffusely throughout the hospital catchment area, with one possible focus of infection identified in Weston, MA. Due to a lack of clinical data reporting to the Massachusetts Department of Public Health, only 20 of 32 HGA cases (63%) fulfilled the case confirmation criteria. CONCLUSION: Diagnosis of HGA requires a high suspicion for infection even in endemic areas. Use of a tick-associated pathogen panel that includes PCR assays for several organisms could improve detection of underrecognized tick-borne diseases in endemic areas. Lack of epidemiological follow-up to confirm corroborating clinical findings prevents accurate case reporting and assessment of the true HGA burden.


Subject(s)
Anaplasma phagocytophilum , Anaplasmosis/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Anaplasmosis/complications , Anaplasmosis/epidemiology , Anaplasmosis/pathology , Anaplasmosis/transmission , Animals , Exanthema/etiology , Exanthema/microbiology , Female , Humans , Leukopenia/etiology , Leukopenia/microbiology , Male , Massachusetts/epidemiology , Middle Aged , Polymerase Chain Reaction , Thrombocytopenia/etiology , Thrombocytopenia/microbiology , Ticks/microbiology , Young Adult
10.
Am J Med ; 123(4 Suppl): S4-15, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20350635

ABSTRACT

Community-acquired pneumonia (CAP) is a common and potentially serious illness with significant human and economic costs to society. The recent collaborative statement from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) represents the most up-to-date evidence-based guidelines from North America, incorporating important advances in the management of patients with CAP. The cases presented in this review highlight many of the recent recommendations from the IDSA/ATS guidelines.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Influenza, Human/diagnosis , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Pneumonia/diagnosis , Pneumonia/drug therapy , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Adult , Aged , Antitubercular Agents/therapeutic use , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Cough/microbiology , Cough/virology , Diagnosis, Differential , Dyspnea , Fatal Outcome , Female , Fever/microbiology , Hemoptysis/microbiology , Humans , Hypotension/microbiology , Influenza, Human/complications , Leukopenia/microbiology , Male , Multiple Organ Failure/microbiology , Mycobacterium tuberculosis/isolation & purification , Pneumonia/microbiology , Pneumonia/therapy , Practice Guidelines as Topic , Respiratory Distress Syndrome/microbiology , Risk Factors , Severity of Illness Index , Smoking/adverse effects , Staphylococcal Infections/microbiology , Staphylococcal Infections/therapy , Tuberculosis, Miliary/diagnosis , Tuberculosis, Miliary/drug therapy
11.
J Biol Chem ; 283(15): 9531-42, 2008 Apr 11.
Article in English | MEDLINE | ID: mdl-18263586

ABSTRACT

Pathology data from the anthrax animal models show evidence of significant increases in vascular permeability coincident with hemostatic imbalances manifested by thrombocytopenia, transient leucopenia, and aggressive disseminated intravascular coagulation. In this study we hypothesized that anthrax infection modulates the activity of von Willebrand factor (VWF) and its endogenous regulator ADAMTS13, which play important roles in hemostasis and thrombosis, including interaction of endothelial cells with platelets. We previously demonstrated that purified anthrax neutral metalloproteases Npr599 and InhA are capable of cleaving a variety of host structural and regulatory proteins. Incubation of human plasma with these proteases at 37 degrees C in the presence of urea as a mild denaturant results in proteolysis of VWF. Also in these conditions, InhA directly cleaves plasma ADAMTS13 protein. Npr599 and InhA digest synthetic VWF substrate FRETS-VWF73. Amino acid sequencing of VWF fragments produced by InhA suggests that one of the cleavage sites of VWF is located at domain A2, the target domain of ADAMTS13. Proteolysis of VWF by InhA impairs its collagen binding activity (VWF:CBA) and ristocetin-induced platelet aggregation activity. In plasma from anthrax spore-challenged DBA/2 mice, VWF antigen levels increase up to 2-fold at day 3 post-infection with toxigenic Sterne 34F(2) strain, whereas VWF:CBA levels drop in a time-dependent manner, suggesting dysfunction of VWF instead of its quantitative deficiency. This conclusion is further supported by significant reduction in the amount of VWF circulating in blood in the ultra-large forms. In addition, Western blot analysis shows proteolytic depletion of ADAMTS13 from plasma of spore-challenged mice despite its increased expression in the liver. Our results suggest a new mechanism of anthrax coagulopathy affecting the levels and functional activities of both VWF and its natural regulator ADAMTS13. This mechanism may contribute to hemorrhage and thrombosis typical in anthrax.


Subject(s)
ADAM Proteins/metabolism , Anthrax/enzymology , Bacterial Proteins/metabolism , Disseminated Intravascular Coagulation/enzymology , Metalloproteases/metabolism , von Willebrand Factor/metabolism , ADAMTS13 Protein , Animals , Anthrax/pathology , Anti-Bacterial Agents/pharmacology , Blood Platelets/metabolism , Blood Platelets/microbiology , Blood Platelets/pathology , Cell Communication/drug effects , Collagen/metabolism , Disease Models, Animal , Disseminated Intravascular Coagulation/microbiology , Disseminated Intravascular Coagulation/pathology , Endothelial Cells/metabolism , Endothelial Cells/microbiology , Endothelial Cells/pathology , Hemostasis/drug effects , Humans , Leukopenia/enzymology , Leukopenia/microbiology , Leukopenia/pathology , Metalloendopeptidases/metabolism , Mice , Plasma/enzymology , Plasma/microbiology , Platelet Aggregation/drug effects , Protein Binding/drug effects , Protein Structure, Tertiary , Ristocetin/pharmacology , Spores, Bacterial/enzymology , Substrate Specificity/drug effects , Thrombocytopenia/enzymology , Thrombocytopenia/microbiology , Thrombocytopenia/pathology , Thrombosis/enzymology , Thrombosis/microbiology , Thrombosis/pathology , Time Factors , Urea/pharmacology
14.
J Trauma ; 56(5): 931-4; discussion 934-6, 2004 May.
Article in English | MEDLINE | ID: mdl-15179229

ABSTRACT

BACKGROUND: The use of quantitative cultures of the bronchoalveolar lavage (BAL) effluent to distinguish between posttraumatic inflammatory response and ventilator-associated pneumonia (VAP) is becoming more common. However, the diagnostic threshold of either 10 or 10 colonies/mL remains debatable. Because mortality from VAP is related to treatment delay, some have chosen a lower diagnostic threshold (>10 colonies/mL). This may result in unnecessary antibiotic use with its sequelae: increased resistant organisms, antibiotic-related complications, and increased costs. The purpose of this study is to determine the optimal diagnostic threshold for VAP diagnosis using quantitative cultures of the BAL effluent. METHODS: Data on patients with fiberoptic bronchoscopy with BAL are maintained in a prospectively collected database at our Level I trauma center. This database was reviewed for timing and frequency of BAL and the colony counts of each organism identified. Indication for bronchoscopy was clinical evidence of VAP. VAP was defined as >10 colonies/mL in the BAL effluent. A false-negative BAL was defined as any patient who had <10 colonies/mL and developed VAP with the same organism up to 7 days after the previous culture. RESULTS: Over a 46-month period, 526 patients underwent 1,372 fiberoptic bronchoscopy procedures with BAL. Of these, 72% were male patients, 91% followed blunt injury, and mean age and Injury Severity Score were 43 years and 30, respectively. Overall mortality was 14%. There were 1,898 organisms identified (42% were gram-positive and 58% were gram-negative). VAP was diagnosed in 38% of BAL. Overall, there were 43 episodes in 38 patients defined as false-negative (3%). The false-negative rate was 9% in patients with 10 organisms. The most common false-negative organisms were Pseudomonas and Acinetobacter species. CONCLUSION: The VAP diagnostic threshold for quantitative BAL in trauma patients should be >10 colonies/mL. One may consider a threshold of >10 colonies/mL in severely injured patients with Pseudomonas or Acinetobacter species.


Subject(s)
Bronchoalveolar Lavage Fluid/microbiology , Cross Infection/diagnosis , Cross Infection/etiology , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/etiology , Ventilators, Mechanical/adverse effects , Adult , Age Distribution , Colony Count, Microbial , Cross Infection/epidemiology , Diagnosis, Differential , Drug Resistance , False Negative Reactions , False Positive Reactions , Female , Fever/microbiology , Hospital Mortality , Humans , Injury Severity Score , Leukocytosis/microbiology , Leukopenia/microbiology , Male , Microbial Sensitivity Tests , Pneumonia, Bacterial/epidemiology , Prospective Studies , Sensitivity and Specificity , Sex Distribution , Tennessee/epidemiology , Time Factors , Trauma Centers
15.
Antimicrob Agents Chemother ; 48(5): 1876-8, 2004 May.
Article in English | MEDLINE | ID: mdl-15105148

ABSTRACT

We evaluated the virulence of Pseudomonas aeruginosa carrying bla(IMP), a metallo-beta-lactamase gene, and the efficacy of ceftazidime, imipenem-cilastatin, and ciprofloxacin in the endogenous bacteremia model. The presence of bla(IMP) did not practically change the virulence of the parent strain, and ciprofloxacin was effective against infection with P. aeruginosa carrying bla(IMP).


Subject(s)
Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/metabolism , Pseudomonas aeruginosa/pathogenicity , beta-Lactamases/metabolism , Animals , Bacteremia/drug therapy , Bacteremia/microbiology , Ceftazidime/therapeutic use , Cephalosporins/therapeutic use , Cilastatin/therapeutic use , Ciprofloxacin/therapeutic use , Drug Therapy, Combination , Imipenem/therapeutic use , Leukopenia/complications , Leukopenia/microbiology , Male , Mice , Mice, Inbred BALB C , Protease Inhibitors/therapeutic use , Pseudomonas aeruginosa/genetics , Stem Cells , Thienamycins/therapeutic use
16.
Antimicrob Agents Chemother ; 48(4): 1105-11, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15047508

ABSTRACT

BAL5788 is a water-soluble prodrug of BAL9141, a new broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- and vancomycin-resistant staphylococci and penicillin-resistant streptococci. In plasma BAL5788 is rapidly converted to BAL9141. We studied the activity of BAL5788 in a mouse model of acute pneumococcal pneumonia. Leukopenic female Swiss albino mice were challenged intratracheally with 10(7) CFU of clinical Streptococcus pneumoniae strains P-52181 (Pen(s) Cro(s) Ctx(s)), P-15986 (Pen(r) Cro(s) Ctx(s)), P-40422 (Pen(r) Cro(r) Ctx(r)), and P-40984 (Pen(r) Cro(r) Ctx(r)). Infected mice received subcutaneous (s.c.) injections of BAL5788 or ceftriaxone starting 3 h after pneumococcal challenge. Uninfected nonleukopenic mice received single s.c. doses of BAL5788 to determine the BAL9141 concentration-time profiles in serum and lungs. Untreated control mice died within 5 days postinfection. Ten-day cumulative survival rates for infected mice receiving BAL5788 (total daily doses of BAL9141 equivalents, 2.1 to 75 mg/kg of body weight) ranged from 57 to 100%, whereas with ceftriaxone (total daily doses, 10 to 400 mg/kg), the survival rates varied between 13 and 100%. In mice infected with P-15986, the survival rates achieved with BAL5788 (BAL9141 equivalent, 8.4 mg/kg) and those achieved with ceftriaxone (50 mg/kg) were significantly different (93 versus 13%; P < 0.0001) in favor of BAL5788; the outcomes of the trials with all other strains were not significantly different between the two antibiotics, but markedly lower doses of BAL5788 than ceftriaxone were required to obtain similar survival rates. Pharmacokinetic data showed that BAL9141 was effective against the four pneumococcal strains tested at very low values of the time above the MIC (T > MIC), which ranged from 9 to 18% of the dosing interval, whereas the values of T > MICs for ceftriaxone ranged from 30 to 50% of the dosing interval.


Subject(s)
Cephalosporins/therapeutic use , Pneumonia, Pneumococcal/drug therapy , Prodrugs/therapeutic use , Animals , Ceftriaxone/therapeutic use , Cephalosporin Resistance , Cephalosporins/pharmacokinetics , Female , Injections, Subcutaneous , Leukopenia/microbiology , Lung/microbiology , Mice , Microbial Sensitivity Tests , Pneumonia, Pneumococcal/microbiology , Prodrugs/pharmacokinetics , Streptococcus pneumoniae/drug effects , Survival Analysis
17.
J Antimicrob Chemother ; 53(2): 311-7, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14729753

ABSTRACT

OBJECTIVES: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus. METHODS: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded. RESULTS: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg). CONCLUSIONS: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.


Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Amphotericin B/pharmacology , Amphotericin B/toxicity , Animals , Antifungal Agents/pharmacology , Antifungal Agents/toxicity , Aspergillosis/microbiology , Aspergillus/drug effects , Immunocompetence , Immunosuppression Therapy , Leukopenia/microbiology , Male , Maximum Tolerated Dose , Mice , Microbial Sensitivity Tests , Survival Analysis
18.
Pediatr Nephrol ; 18(3): 293-6, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12644928

ABSTRACT

Severe illness with acute renal failure, leukopenia, thrombocytopenia, and coagulopathy frequently occurs with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, hematological malignancies, sepsis, and collagen-vascular diseases. We present a 16-year-old male fast-food worker with underlying chronic renal insufficiency who manifested these abnormalities as a result of Ehrlichia chaffeensis sepsis. Doxycycline therapy and aggressive supportive care led to complete recovery.


Subject(s)
Ehrlichia chaffeensis , Ehrlichiosis/complications , Kidney Failure, Chronic/microbiology , Leukopenia/microbiology , Liver Diseases/microbiology , Thrombocytopenia/microbiology , Adolescent , Anti-Bacterial Agents/pharmacology , Doxycycline/pharmacology , Ehrlichiosis/drug therapy , Humans , Male , Sepsis/microbiology
19.
Lab Invest ; 82(3): 303-11, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11896209

ABSTRACT

The agent of human granulocytic ehrlichiosis (aoHGE) is a tick-borne, obligate intracellular, granulocytotropic bacterium able to infect numerous host species. Given its unique niche and the leukopenia often noted with infection, we investigated the effect of acute aoHGE infection on neutrophil activation by evaluating surface expression of the beta 2 integrin CD11b/CD18 in a mouse model using FACS analysis. Infection resulted in neutrophil activation with up-regulation of CD11b/CD18 in multiple strains of mice, however, hematologic analysis showed no apparent role for CD11b/CD18 in mediating peripheral leukopenia. Because IFN-gamma is an important cytokine during granulocytic ehrlichiosis and is known to activate leukocytes, we investigated the potential role of IFN-gamma in CD11b/CD18 up-regulation. Neutrophils from IFN-gamma knock-out mice became activated during aoHGE infection, however, the kinetics of activation differed from wild-type mice. In addition, activation correlated directly with the presence of bacteria because neutrophils with large intracytoplasmic morula also expressed higher levels of CD11b/CD18. CD11b/CD18 seemed to be critical to early bacterial clearance and killing in vivo because infection of mice with targeted genetic disruption of CD11b/CD18 resulted in an initial increase in bacterial burden compared with wild-type mice. Similarly, in vitro culture of neutrophils from infected CD11b/CD18 knock-out mice resulted in a marked increase in bacterial proliferation compared with congenic controls. The data support crucial roles of CD11b/CD18 and IFN-gamma-mediated cell activation as mechanisms that limit bacterial replication.


Subject(s)
CD18 Antigens/biosynthesis , Ehrlichiosis/metabolism , Macrophage-1 Antigen/biosynthesis , Animals , DNA, Bacterial/analysis , Disease Models, Animal , Ehrlichia/physiology , Female , Flow Cytometry , Homozygote , Interferon-gamma/genetics , Interferon-gamma/immunology , Kinetics , Leukopenia/immunology , Leukopenia/microbiology , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Neutrophil Activation/immunology , Neutrophils/physiology , Specific Pathogen-Free Organisms , Up-Regulation
20.
Br J Haematol ; 115(1): 53-7, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11722409

ABSTRACT

Procalcitonin (PCT) has proven to be a very sensitive marker of sepsis for non-leucopenic patients. Little is known about its relevance in immunosuppressed and leucopenic adults. Four hundred and seventy-five PCT determinations were carried out in 73 haematological patients: on 221 occasions the white blood cell (WBC) count was < 1.0 x 10(9)/l and on 239 occasions it was > 1.0 x 10(9)/l leucocytes. Patients were classified as: non-systemic infected controls (n = 280), patients with bacteraemia (n = 32), sepsis (n = 30), severe sepsis (n = 3), septic shock (n = 3) and systemic inflammatory response syndrome (SIRS) (n = 62). When the WBC count was > 1.0 x 10(9)/l, gram-negative bacteria induced higher PCT levels (median 9.4 ng/ml) than gram-positives (median 1.4 ng/ml). In cases with a WBC < 1.0 x 10(9)/l, PCT levels were similar for gram-negative and gram-positive bacteria (1.1 ng/ml versus 0.85 ng/ml). Regardless of the leucocyte count, the median PCT level in bacteraemia cases always remained < 0.5 ng/ml. In heavily leucopenic situations, PCT levels were never > 2 ng/ml even in the sepsis and severe sepsis/septic shock groups, whereas a WBC count > 1.0 x 10(9)/l resulted in median PCT values of 4.1 ng/ml and 45 ng/ml respectively. The positive predictive value for sepsis (cut-off 2 ng/ml) was 93% in cases of WBC count > 1.0 x 10(9)/l, but only 66% in leucopenic conditions. The negative predictive value (cut-off 0.5 ng/ml) was 90% when the WBC count was > 1.0 x 10(9)/l and 63% in leucopenic conditions. Procalcitonin is an excellent sepsis marker with a high positive- and negative-predictive value in patients with WBC count > 1.0 x 10(9)/l, but it does not work satisfactorily below this leucocyte count.


Subject(s)
Bacterial Infections/diagnosis , Calcitonin/blood , Leukopenia/blood , Leukopenia/microbiology , Protein Precursors/blood , Bacterial Infections/complications , Bacterial Infections/immunology , Biomarkers/blood , Calcitonin Gene-Related Peptide , Humans , Immunosuppression Therapy , Leukocyte Count , Predictive Value of Tests , Sepsis/diagnosis , Shock, Septic/diagnosis , Statistics, Nonparametric
SELECTION OF CITATIONS
SEARCH DETAIL
...